) .
Neuroleptic malignant syndrome (NMS) is a rare, lifethreatening but potentially treatable condition. This study was performed to investigate the clinical spectrum, antecedent events and outcome of NMS patients admitted in the Neurology department of a large teaching hospital of North India. Fourteen cases of NMS were taken after a thorough search during a three-year period (May 2000 to April 2003). The Incidence of NMS was 1.40/ 1000 patients treated with neuroleptics and mortality rate was 14.28%. Amongst the neuroleptics Haloperidol (parenteral) was implicated as a most common drug for NMS in 57% of patients. An association with coexisting precipitating illness was clearly recorded in 71.4% patients. All the recorded patients of NMS received 500-700 mg CPZ equivalent/day of neuroleptics. NMS as an indiosyncratic phenomenon was noticed in 28% patients. 85.7% responded to dopaminergic drugs along with supportive treatment and showed partial or complete recovery within 7-14 days. In those with partial recovery residual deficits included Parkinsonian features, depression and diaphoresis in a small percentage of patients.
Key words: Fever, neuroleptic malignant syndrome, neuroleptics hazy. [1] Many diagnostic criteria have been proposed, but the lack of universally accepted criteria is perhaps the most serious drawback for study of this condition.
Much of the understanding of this disorder is based on review and case series from the western countries.
[3]
Noticeable among the reports from other countries is a prospective study from China [4] fluphenazine deconoate as the major risk factor. There have been few individual case reports [5, 6] short series [7, 8] and reviews [9] from India but no systematic data is available till date except those given by Chopra et al.
Observations and Discussion
This study was conducted at the SMS Medical College Hospital, a large teaching hospital of North India. All patients with symptom complex suggestive of NMS were analyzed in detail between the year 2001-2003 and a total of 14 patients were confirmed to have NMS on the basis of Caroff and Mann criteria [2] [ Table 1 ] and after excluding various NMS-simulating diseases (heat stroke, acute anticholinergic syndrome, catatonia, status epilepticus, encephalitis, etc.). A detailed analysis of these cases was Neuroleptic malignant syndrome (NMS) has attracted widespread attention among neurologists and psychiatrists in the last few years. Over the last decade, 1000 cases of NMS have been reported. [1] It is a potentially life-threatening complication of neuroleptic drugs. The frequency and mortality of NMS among neuroleptic drug users has been recorded around 0.5-2.4% and 4-30% [2] respectively. This disorder is recognized as a hypodopaminergic state characterized by muscle rigidity, hyperthermia, altered sensorium, autonomic instability and elevated serum creatinine phosphokinase (CPK) levels; the details of this clinical syndrome still remain made including evaluation of coexistent systemic or organic brain syndromes. The purpose of this study is to highlight clinical and prognostic aspects of NMS and to increase awareness among physicians, neurologists and psychiatrists about this under-recognized complication of neuroleptic medication, which if diagnosed in time can be treated successfully.
Characteristics of patients who developed NMS are summarized in Tables 2 and 3 . The incidence rate obtained et al.
[8] Most of the patients were given high potency neuroleptics (HPD, CPZ) for the first time for different reasons by parenteral route as earlier noticed by Keck et al. [10] Haloperidol was the most common drug incriminated. Idiosyncratic phenomenon was noticed in 28% cases, an observation earlier documented in a short series.
[11] Fifty-six per cent (9 out of 14) of our patients showed moderate to severe dehydration. Presence of dehydration predisposes to NMS because the decreased blood volume induces peripheral vasoconstriction which was 1.40/1000 cases treated with neuroleptics, a finding impairs heat dissipation. In our series, five patients of matching with the retrospective study by Chopra et al, [8] encephalitis developed classical features of NMS. Such although relatively low incidence has been documented association has been rarely noticed earlier. Neuroleptic in prospective studies. [10] A comparatively higher malignant syndrome is known to occur as a result of a incidence in the present prospective study could be hypodopaminergic state caused by a neuroleptic. A because of the inclusion of spectrum concept of NMS in relative hydopaminergic state in encephalitic illness can the study, including incipient, mild cases to profoundly be thought of, which might have led to the association of ill patients. The majority of patients who developed NMS encephalitic illness with NMS. [12, 13] One patient developed were male (64.28%) and were below 40 years of age NMS on the background of alcoholism; it could be as a (85.7%). Similar findings were noticed early by Chopra result of increased susceptibility of the skeletal muscle to neuroleptics under the effect of alcohol as postulated in in the early stage. Although newer/ atypical neuroleptics have been introduced to avoid this dreaded complication they have also been infrequently incriminated in causation of NMS in a few case reports. [14, 15] Like some previous studies the time range of neuroleptic treatment was one to three days prior to development of NMS more so if high potency neuroleptics were administered for the first time. In addition, antiemetic drug Metaclopromide ingestion preceded the illness in four (28%) patients as earlier pointed out by Nehru et al. [9] Fever, altered sensorium and rigidity were the cardinal up dosage (after 5-20 mg/day) along with supportive treatment such as fever reduction, hydration and maintenance of nutrition was given to all the patients at the earliest. Recovery was noticed in 12 (85.7%) patients, As compared to recovery documented in 75-82% of cases elsewhere. Inclusion of relatively less severe cases of the spectrum of NMS in our study might have caused higher percentage of recovery. Recovery was complete in the majority of cases (79%) and partial in 21% of cases. Residual symptoms and signs like Parkinsonian features (three patients), depression (one patient) and diaphoresis features of all cases, a finding matching with earlier (two patients) were noticed on subsequent follow-up. studies. However, oromandibular dyskinesia (7%), Residual extrapyramidal features have been described in myokymia (7%) and seizures (14%) were some unusual other studies as well. [4] observations recorded in the present study.
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